Emergency: 911
Telecare: 811
Poison: 1-800-565-8161
5850/5980 University Ave., Halifax, NS B3K 6R8

Utilization Management Program: Palivizumab (Synagis®)

Utilization Management Program for Respiratory Syncytial Virus Immunoprophylaxis in Nova Scotia (2022-2023)

Updated November 2022

In October 2003, the Department of Health requested that the utilization of palivizumab be monitored.

In April 2004 the Nova Scotia Provincial Blood Coordinating Program convened a provincial working group of medical specialists, including pediatricians and neonatologists, to review Respiratory Syncytial Virus (RSV) prophylaxis cost and utilization data for Nova Scotia, to develop a Provincial RSV Infection Prophylaxis guideline and assist in the designing of a utilization management program for RSV immunoprophylaxis products.

The working group reviews the results of monitoring for the RSV season each June and consider if revisions are necessary for the Provincial RSV Infection Prophylaxis Guidelines and utilization management program for the next RSV season. IWK Health will continue the utilization management program initiated by the NSPBCP.

The utilization management program consists of the following components:

  1. Provincial Guidelines for RSV Infection Prophylaxis including: 
    • Indications for use 
    • Approval processes 
    • Nova Scotia request form 
    • Defined and monitored provincial start and end to the RSV season 
    • Inventory management strategies and processes 
    • Administration guidelines 
    • Storage guidelines 
    • Reporting of adverse events
  2. Communication/Education to key stakeholders
  3. Monitoring and Reporting of palivizumab cost and utilization data